MedWatch

ALK CEO after upgrade: "In spite of Covid-19, ALK is on a roll – I'm really proud"

A broad effort across the organization and high tablet sales cause ALK to raise its guidance for its 2020 earnings. However, postponed costs and reduced travel activity contribute to the upgrade, which might have been even larger had it not been for Covid-19, says CEO.

ALK President and CEO Carsten Hellman | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

Things are going so well for the allergy company ALK that the firm told the market Thursday morning that it was raising its full-year earnings guidance.

Whereas the company used to expect an operational result (earnings before interest, taxes, depreciations, amortizations, -ed.) at DKK 300-350m (USD 47.8m-55.8m), ALK now guides for DKK 350-400m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs